Medtronic PLC

Medtronic plc announced its fourth quarter and full year fiscal 2026 results, showcasing 8.4% reported revenue growth for the full year and delivering the highest annual revenue growth in a decade.

Medtronic revised its fiscal year 2026 non-GAAP EPS guidance downwards following early FDA clearance of MiniMed Flex and related financial impacts.

Medtronic plc reported robust third quarter fiscal 2026 results, surpassing revenue and non-GAAP EPS guidance, driven by strong cardiovascular performance and strategic product clearances.

Medtronic plc reported strong second quarter fiscal year 2026 financial results, exceeding revenue and EPS expectations and raising its full-year guidance.

Medtronic plc announced the retirement of Gregory L. Smith, Executive Vice President of Enterprise Operations, effective December 2, 2025.

Medtronic plc shareholders overwhelmingly approved amendments to the company's Articles of Association and re-elected all directors at its 2025 Annual General Meeting.

Medtronic plc reported increased net sales in the third quarter and first nine months of fiscal year 2026, driven by strong segment growth, but net income and diluted EPS declined.

Medtronic plc announced robust financial results for the second quarter and first half of fiscal year 2026, driven by strong segment performance and progress on its Diabetes business separation.

Medtronic plc announced an 8% increase in net sales and a 13% rise in operating profit for Q1 FY26, alongside a significant patent litigation victory and progress on its Diabetes business separation.

Medtronic's Q3 2025 results reveal growth in net sales and earnings per share, driven by strong performance in key segments.

Medtronic's second quarter fiscal year 2025 results show a 5% increase in net sales and diluted earnings per share of $0.99, driven by growth in several key business segments.

Medtronic's first quarter of fiscal year 2025 saw a 3% increase in net sales, driven by strong performance in Diabetes and Neuromodulation, despite a negative impact from Italian payback accruals.

Medtronic plc reported robust financial results for fiscal year 2026, driven by significant growth across its key business segments.

Medtronic plc reported a 4% increase in net sales and a significant rise in GAAP net income for fiscal year 2025, fueled by strong performance in its Cardiovascular, Neuroscience, and Diabetes segments, while also announcing plans to separate its Diabetes business.

Medtronic's 2024 annual report details its financial performance, strategic initiatives, and various risk factors impacting its global operations.

Michelle Quinn, EVP, GC and Secretary of Medtronic plc, reported a transaction in 2,069 shares of common stock on July 28, 2026.

Medtronic plc reports a transaction where SVP, Chief HR Officer Walter Matthew R. sold 3,102 ordinary shares.

Medtronic plc executive Harry Skip Kiil reported the sale of company shares on June 8, 2026, totaling 4,189 ordinary shares.

EVP & President of Cardiovascular Harry Skip Kiil disposed of 6,817 Medtronic shares to cover tax obligations.

Medtronic Chairman and CEO Martha Geoffrey reported the withholding of 41,936 shares to cover tax obligations related to vested restricted stock units.

Medtronic EVP Michael Marinaro disposed of 7,471 shares to satisfy tax obligations related to vested restricted stock units.

Medtronic plc has filed definitive additional proxy soliciting materials with the SEC.

Medtronic plc announces its 2025 Annual General Meeting agenda, highlighting strong fiscal year 2025 performance, executive compensation, and proposals for corporate governance and capital structure adjustments.

Medtronic plc has filed a definitive proxy statement with the SEC regarding its upcoming shareholder meeting.

Medtronic's 2024 proxy statement outlines proposals for the annual general meeting, including director elections, auditor ratification, executive compensation approval, and share issuance authorizations.

Medtronic plc, through its affiliate Covidien Group S.a.r.l., has acquired a 16.2% stake in Anteris Technologies Global Corp. for $90 million, establishing a strategic partnership.

Medtronic plc has filed a Schedule 13G reporting beneficial ownership of 90% of the outstanding common stock of MiniMed Group, Inc.

Vanguard Capital Management has disclosed beneficial ownership of 96,424,044 shares, representing 7.51% of Medtronic PLC's common stock as of March 31, 2026.

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Medtronic PLC following an internal corporate realignment.

Medtronic plc and Covidien Group S.a.r.l. have jointly reported a beneficial ownership of 17.8% in Orchestra BioMed Holdings, Inc. common stock.

The Vanguard Group has filed an amendment to its Schedule 13G, reporting a beneficial ownership of 10.21% in Medtronic PLC common stock.

BlackRock, Inc. has filed an amended Schedule 13G, revealing its beneficial ownership of 6.9% of Medtronic plc's common stock as of March 31, 2025.